Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biofrontera Inc BFRI

Healthcare
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial... see more

Recent & Breaking News (NDAQ:BFRI)

Biofrontera Inc. Announces Notice of Allowance for U.S. Method-of-Use Patent on PDT-lamp

GlobeNewswire December 8, 2021

Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz®

GlobeNewswire December 6, 2021

Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination Protocol

GlobeNewswire December 2, 2021

Biofrontera Inc. Announces Closing of $15 Million Private Placement

GlobeNewswire December 1, 2021

Biofrontera Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire November 30, 2021

Biofrontera Inc. Pricing of $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire November 29, 2021

Biofrontera Inc. to Report Third Quarter Financial Results on November 30, 2021

GlobeNewswire November 23, 2021

Biofrontera Kicks Off US Clinical Study Program for Ameluz®

GlobeNewswire November 16, 2021

Biofrontera Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Warrants

GlobeNewswire November 2, 2021

Biofrontera Inc. Announces Pricing of $18.0 Million Initial Public Offering

GlobeNewswire October 28, 2021